TECENTRIQ SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

ATEZOLIZUMAB

可用日期:

HOFFMANN-LA ROCHE LIMITED

ATC代码:

L01FF05

INN（国际名称）:

ATEZOLIZUMAB

剂量:

840MG

药物剂型:

SOLUTION

组成:

ATEZOLIZUMAB 840MG

给药途径:

INTRAVENOUS

每包单位数:

15G/50G

处方类型:

Prescription

治疗领域:

ANTINEOPLASTIC AGENTS

產品總結:

Active ingredient group (AIG) number: 0158930001; AHFS:

授权状态:

APPROVED

授权日期:

2019-09-19

产品特点

_Pr_
_Tecentriq_
_®_
_ (atezolizumab for injection) _
_Page 1 of 110_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TECENTRIQ®
atezolizumab for injection
Concentrate for solution for infusion, 60 mg/mL
1200 mg/20 mL and 840 mg/14 mL single use vials
For intravenous infusion
Professed Standard
ATC Code: L01FF05
Antineoplastic agent, monoclonal antibody
Hoffmann-La Roche Limited
7070 Mississauga Road
Mississauga, Ontario, Canada
L5N 5M8
www.rochecanada.com
Date of Initial Authorization:
Apr 12, 2017
Date of Revision:
Mar 13, 2024
Submission Control Number: 273807
TECENTRIQ® is a registered trademark of F. Hoffmann-La Roche AG, used
under license
©
Copyright 2023, Hoffmann-La Roche Limited
_ _
_Pr_
_Tecentriq_
_®_
_ (atezolizumab for injection) _
_Page 2 of 110_
RECENT MAJOR LABEL CHANGES
1 Indications
12/2022
4 Dosage and Administration
03/2024
4 Dosage and Administration, 4.2 Recommended Dose and
Dosage Adjustment
03/2024
4 Dosage and Administration, 4.3 Reconstitution
03/2024
7 Warnings and Precautions
03/2024
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................................
2
TABLE OF CONTENTS
...........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................................................
4
1
INDICATIONS
..........................................................................................................................
4
1.1
Pediatrics
.........................................................................................................................5
1.2
Geriatrics
.........................................................................................................................5
2
CONTRAINDICATIONS
...................................................